These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 21901986)
1. Valproic acid inhibits prostate cancer cell migration by up-regulating E-cadherin expression. Zhang L; Wang G; Wang L; Song C; Wang X; Kang J Pharmazie; 2011 Aug; 66(8):614-8. PubMed ID: 21901986 [TBL] [Abstract][Full Text] [Related]
2. Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion. Hudak L; Tezeeh P; Wedel S; Makarević J; Juengel E; Tsaur I; Bartsch G; Wiesner C; Haferkamp A; Blaheta RA Prostate; 2012 Dec; 72(16):1719-35. PubMed ID: 22473339 [TBL] [Abstract][Full Text] [Related]
3. Involvement of HDAC1 in E-cadherin expression in prostate cancer cells; its implication for cell motility and invasion. Kim NH; Kim SN; Kim YK Biochem Biophys Res Commun; 2011 Jan; 404(4):915-21. PubMed ID: 21184735 [TBL] [Abstract][Full Text] [Related]
4. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells. Chen CL; Sung J; Cohen M; Chowdhury WH; Sachs MD; Li Y; Lakshmanan Y; Yung BY; Lupold SE; Rodriguez R J Pharmacol Exp Ther; 2006 Nov; 319(2):533-42. PubMed ID: 16868035 [TBL] [Abstract][Full Text] [Related]
6. Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo. Gao D; Xia Q; Lv J; Zhang H Int J Urol; 2007 Sep; 14(9):838-45. PubMed ID: 17760752 [TBL] [Abstract][Full Text] [Related]
7. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369 [TBL] [Abstract][Full Text] [Related]
8. Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer. Wedel S; Hudak L; Seibel JM; Juengel E; Oppermann E; Haferkamp A; Blaheta RA Prostate; 2011 May; 71(7):722-35. PubMed ID: 20954195 [TBL] [Abstract][Full Text] [Related]
9. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. Thelen P; Schweyer S; Hemmerlein B; Wuttke W; Seseke F; Ringert RH Int J Oncol; 2004 Jan; 24(1):25-31. PubMed ID: 14654937 [TBL] [Abstract][Full Text] [Related]
10. Valproic acid inhibits the proliferation of cancer cells by re-expressing cyclin D2. Witt D; Burfeind P; von Hardenberg S; Opitz L; Salinas-Riester G; Bremmer F; Schweyer S; Thelen P; Neesen J; Kaulfuss S Carcinogenesis; 2013 May; 34(5):1115-24. PubMed ID: 23349020 [TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma. Angelucci A; Muzi P; Cristiano L; Millimaggi D; Cimini A; Dolo V; Miano R; Vicentini C; Cerù MP; Bologna M Prostate; 2008 May; 68(6):588-98. PubMed ID: 18288684 [TBL] [Abstract][Full Text] [Related]
12. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line. Valentini A; Biancolella M; Amati F; Gravina P; Miano R; Chillemi G; Farcomeni A; Bueno S; Vespasiani G; Desideri A; Federici G; Novelli G; Bernardini S Drug Metab Dispos; 2007 Jun; 35(6):968-72. PubMed ID: 17371798 [TBL] [Abstract][Full Text] [Related]
13. Cellular and molecular mechanisms of pomegranate juice-induced anti-metastatic effect on prostate cancer cells. Wang L; Alcon A; Yuan H; Ho J; Li QJ; Martins-Green M Integr Biol (Camb); 2011 Jul; 3(7):742-54. PubMed ID: 21594291 [TBL] [Abstract][Full Text] [Related]
14. Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Xia Q; Sung J; Chowdhury W; Chen CL; Höti N; Shabbeer S; Carducci M; Rodriguez R Cancer Res; 2006 Jul; 66(14):7237-44. PubMed ID: 16849572 [TBL] [Abstract][Full Text] [Related]
15. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells. Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Prieto JC; Carmena MJ Prostate; 2009 May; 69(7):774-86. PubMed ID: 19189304 [TBL] [Abstract][Full Text] [Related]
16. Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4. Lan X; Lu G; Yuan C; Mao S; Jiang W; Chen Y; Jin X; Xia Q J Cancer Res Clin Oncol; 2016 Jan; 142(1):177-85. PubMed ID: 26206483 [TBL] [Abstract][Full Text] [Related]
17. Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid. Jones J; Bentas W; Blaheta RA; Makarevic J; Hudak L; Wedel S; Probst M; Jonas D; Juengel E Int J Mol Med; 2008 Sep; 22(3):293-9. PubMed ID: 18698487 [TBL] [Abstract][Full Text] [Related]
18. Valproic acid inhibits human hepatocellular cancer cells growth in vitro and in vivo. Machado MC; Bellodi-Privato M; Kubrusly MS; Molan NA; Tharcisio T; de Oliveira ER; D'Albuquerque LA J Exp Ther Oncol; 2011; 9(2):85-92. PubMed ID: 21699015 [TBL] [Abstract][Full Text] [Related]
19. HDAC inhibitors induce epithelial-mesenchymal transition in colon carcinoma cells. Ji M; Lee EJ; Kim KB; Kim Y; Sung R; Lee SJ; Kim DS; Park SM Oncol Rep; 2015 May; 33(5):2299-308. PubMed ID: 25813246 [TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. Catalano MG; Fortunati N; Pugliese M; Marano F; Ortoleva L; Poli R; Asioli S; Bandino A; Palestini N; Grange C; Bussolati B; Boccuzzi G J Clin Endocrinol Metab; 2012 Jul; 97(7):E1150-9. PubMed ID: 22563106 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]